10.1016/j.molcel.2006.12.009 80 HsuS
Emerging research suggests that GLP-1RAs may also be beneficial in treating conditions like obstructive sleep apnea (Malhotra et al., 2024), osteoarthritis (Bliddal et al., 2024), metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis with liver fibrosis (MASH) (Loomba et al., 2024), polycystic ovary syndrome (PCOS) (Szczesnowicz et al., 2023), Alzheimers disease (Liang et al., 2024), Parkinsons disease (Kalinderi et al., 2024), and addiction (Klausen et al., 2022)
Our findings revealed that all agents and relevant combinations (i.e., GEP44 and GEP12 with Y1-R antagonists or Ex-4 alone) resulted in decreased glucagon release
Do you have people come in and they're like, "Listen, I've got a wedding in six months and I've got 10 pounds that just won't leave